MetaCap

Belite Bio (BLTE) vs Supernus (SUPN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Belite Bio (BLTE) has outperformed Supernus (SUPN) over the past year, gaining 5.7% versus a loss of 36.9%. Supernus is the larger company by market cap ($5.94 billion vs $5.17 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLTE+5.66%SUPN-36.87%
+66%+9%-47%
Nov 21, 20251 yearNov 20, 2026
BLTE+1102.83%SUPN+2.54%
+1815%+856%-103%
Apr 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLTE versus SUPN key metrics
MetricBLTESUPN
Share price$127.38$28.61
Market cap$5.17B$5.94B
1-day change-15.65%+0.92%
YTD return-20.37%-42.43%
1-year return+5.66%-36.87%
5-year return—-6.53%
Forward P/E—7.15
EPS (TTM)$-2.84$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$718.95M
Revenue growth (YoY)—+8.63%
Net income (latest FY)$-77.61M$-38.55M
Gross margin—89.63%
Operating margin—-8.66%
Net margin—-5.36%
52-week high$200.00$42.81
52-week low$115.41$25.92
Distance from 52-week high-36.31%-33.17%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+82.92%+89.23%
Average volume195.65K2.77M
Shares outstanding40.61M207.72M
Employees41827
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BLTE has outperformed SUPN by 42.5 percentage points over the past year.

About Belite Bio

BLTE stock →

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees

About Supernus

SUPN stock →

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees

BLTE vs SUPN FAQ

Which is bigger, Belite Bio or Supernus?

Supernus (SUPN) is larger, with a market capitalization of $5.94B compared with $5.17B for Belite Bio (BLTE).

Which stock has performed better over the past year, BLTE or SUPN?

BLTE returned +5.66% over the past 12 months, compared with -36.87% for SUPN (price return, excluding dividends). Past performance does not predict future results.

Are Belite Bio and Supernus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons